首页> 美国卫生研究院文献>Frontiers in Genetics >A Single-Subject Method to Detect Pathways Enriched With Alternatively Spliced Genes
【2h】

A Single-Subject Method to Detect Pathways Enriched With Alternatively Spliced Genes

机译:单主体方法来检测富含选择性剪接基因的途径

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

RNA-Sequencing data offers an opportunity to enable precision medicine, but most methods rely on gene expression alone. To date, no methodology exists to identify and interpret alternative splicing patterns within pathways for an individual patient. This study develops methodology and conducts computational experiments to test the hypothesis that pathway aggregation of subject-specific alternatively spliced genes (ASGs) can inform upon disease mechanisms and predict survival. We propose the N-of-1-pathways Alternatively Spliced (N1PAS) method that takes an individual patient’s paired-sample RNA-Seq isoform expression data (e.g., tumor vs. non-tumor, before-treatment vs. during-therapy) and pathway annotations as inputs. N1PAS quantifies the degree of alternative splicing via Hellinger distances followed by two-stage clustering to determine pathway enrichment. We provide a clinically relevant “odds ratio” along with statistical significance to quantify pathway enrichment. We validate our method in clinical samples and find that our method selects relevant pathways (p < 0.05 in 4/6 data sets). Extensive Monte Carlo studies show N1PAS powerfully detects pathway enrichment of ASGs while adequately controlling false discovery rates. Importantly, our studies also unveil highly heterogeneous single-subject alternative splicing patterns that cohort-based approaches overlook. Finally, we apply our patient-specific results to predict cancer survival (FDR < 20%) while providing diagnostics in pursuit of translating transcriptome data into clinically actionable information. Software available at .
机译:RNA测序数据提供了实现精密医学的机会,但是大多数方法仅依赖基因表达。迄今为止,还没有方法可以识别和解释单个患者通路中的其他剪接模式。这项研究开发了方法论并进行了计算实验,以检验这一假设,即特定于受试者的选择性剪接基因(ASG)的途径聚集可以告知疾病机制并预测存活率。我们提出了N条途径的1条途径选择性剪接(N1PAS)方法,该方法采用单个患者的配对样品RNA-Seq同种型表达数据(例如,肿瘤vs非肿瘤,治疗前vs治疗期间)和路径注释作为输入。 N1PAS通过Hellinger距离量化替代剪接的程度,然后通过两阶段聚类确定途径富集。我们提供临床上相关的“比值比”以及具有统计学意义的定量途径富集途径。我们在临床样本中验证了我们的方法,发现我们的方法选择了相关途径(在4/6数据集中p <0.05)。广泛的蒙特卡洛研究表明,N1PAS在有效控制错误发现率的同时,可以强大地检测ASG的途径富集。重要的是,我们的研究还揭示了基于同类队列的方法忽略的高度异构的单对象替代剪接模式。最后,我们将患者特定的结果用于预测癌症存活率(FDR <20%),同时提供诊断手段,以寻求将转录组数据转化为可用于临床的信息。可从下载的软件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号